BOULDER, CO -- (Marketwired) -- 10/29/13 -- MBio Diagnostics, Inc. announced the formation of a Scientific Advisory Board (SAB) composed of medical professionals with deep expertise in global health issues. The SAB will help advance MBio Diagnostics' mission to increase access to quality healthcare by delivering innovative and low cost point-of-care (POC) diagnostics. Board members will assist the management team with assessing technology options, developing new POC diagnostics in limited-resource settings, and will provide expertise on future clinical diagnostics trends.
"The creation of a Scientific Advisory Board is essential to our future successes because science is the basis of our innovative point-of-care diagnostics," said Chris Myatt, Founder and CEO of MBio Diagnostics. "The Board's guidance and insights will contribute greatly to our scientific advancements while ensuring that our products meet MBio Diagnostics' global customer needs."
Robert T. Schooley, M.D.
Robert Schooley, M.D. is the Division Head and Professor of Medicine in the Department of Medicine, Division of Infectious Disease, at the University of California, San Diego (UCSD). Dr. Schooley received his medical degree from the Johns Hopkins University School of Medicine and completed fellowships at the National Institute of Allergy and Infectious diseases and at the Massachusetts General Hospital before joining the faculty of Harvard Medical School. Dr. Schooley's personal research interests include HCV, influenza and HIV pathogenesis, and therapy infections that cause morbidity and mortality in resources limited settings. Dr. Schooley is also a member of the PEPFAR Scientific Advisory Board.
Constance Benson, M.D.
Dr. Benson, M.D. is a Professor of Medicine, Senior Attending Physician, and the Infectious Disease Fellowship Training Program Director in the Department of Medicine/Division of Infectious Disease at the University of California, San Diego School of Medicine. She is the principal investigator and Chair of the Executive Committee and Vice Chair of the Scientific Steering Committee of the NIH/NIAID AIDS Clinical Trials Group (ACTG), and is a past chair of the NIH Office of AIDS Research Advisory Council.
Bruce Walker, M.D.
Bruce Walker, M.D. is the Director of the Ragon Institute of MGH, MIT, and Harvard, a Professor of Medicine at Harvard Medical School, and a Howard Hughes Medical Institute Investigator. In addition to his clinical duties as a board certified Infectious Disease specialist, his research focuses on cellular immune responses in chronic viral infections, with a particular focus on HIV. Dr. Walker is also an Adjunct Professor at the Nelson Mandela School of Medicine in Durban, South Africa. He is a member of the Steering Committee for KwaZulu-Natal Research Institute for TB and HIV in South Africa.
MBio Diagnostics, Inc. (www.mbiodx.com) is a privately held diagnostics and life sciences company based in Boulder, CO. MBio Diagnostics is increasing access to quality healthcare by delivering innovative and low cost point-of-care (POC) diagnostics. The MBio System is initially being commercialized to manage treatment of HIV patients from a single drop of blood. The MBio elegant detection system is being developed for a broad menu of applications including multiplex assays and cellular analysis.